This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 7, 2020, and they are subject to change as new information is published.

This session will cover some new data regarding treatment of type 2 diabetes: the GRADE study, SURPASS phase 3 program, the STEP program for treatment of obesity. It will also provide an update on studies using SGLT2 inhibitors and GLP 1 receptor agonists in people with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.

Practice-changing updates to the medical literature that are hot off the presses! Join Dr. Pam Kushner to discuss important changes in the 2021 ADA guidelines and examine recently published research on atrial fibrillation, lipids, reducing cardiovascular risk, coconut oil, patient communication, and much more!

Practice-changing updates to the medical literature that are hot off the presses! Join Dr. Pam Kushner to discuss important changes in the 2021 ADA guidelines and examine recently published research on atrial fibrillation, lipids, reducing cardiovascular risk, coconut oil, patient communication, and much more!

Maximum 50 words to introduce the activity The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm.

The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs.

Join Dr. Sanjiv Chopra, hepatologist, author, speaker, and thought leader as he interviews his guest, Dr. Martin Abrahamson, endocrinologist and associate professor at Harvard Medical School as they discuss major advances in diabetes as well as the promise of stem cell treatment, diet and weight loss in patients with diabetes, and advances in continuous glucose monitoring. The pair will end their conversation discussing what they have learned from patients over the years.

The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm. Learners will have the opportunity to evaluate their knowledge through multiple-choice and matching questions and case-based application.